Advertisement
JAZZ vs JBIO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Hold and JBIO is a Hold.
JAZZ in upward trend: price rose above 50-day moving average on November 06, 2026
JAZZ moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 66%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on JAZZ as a result. In 57 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 58%.
The Moving Average Convergence Divergence (MACD) for JAZZ just turned positive on October 29, 2026. Looking at past instances where JAZZ's MACD turned positive, the stock continued to rise in 31 of 49 cases over the following month. The odds of a continued upward trend are 63%.
Following a +4.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in 176 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
JAZZ broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JAZZ entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.174) is normal, around the industry mean (3.498). P/E Ratio (15.435) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.407) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
JBIO's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for JBIO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 20 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on JBIO as a result. In 78 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for JBIO just turned positive on October 08, 2026. Looking at past instances where JBIO's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
JBIO moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where JBIO advanced for three days, in 219 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for JBIO moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
JBIO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JBIO entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.179) is normal, around the industry mean (3.498). P/E Ratio (-14.084) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. JBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
JAZZ | ||
|---|---|---|
OUTLOOK RATING 1..100 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 28 | |
SMR RATING 1..100 | 44 | |
PRICE GROWTH RATING 1..100 | 40 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| JAZZ | JBIO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 52% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 61% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 58% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 63% | 3 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 83% |
| Advances ODDS (%) | 2 days ago 59% | 2 days ago 82% |
| Declines ODDS (%) | 17 days ago 55% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 80% |
| Aroon ODDS (%) | 2 days ago 60% | 2 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JAZZ’s FA Score shows that 1 FA rating(s) are green while JBIO’s FA Score has 2 green FA rating(s).
- JAZZ’s FA Score: 1 green, 4 red.
- JBIO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JAZZ’s TA Score shows that 4 TA indicator(s) are bullish while JBIO’s TA Score has 5 bullish TA indicator(s).
- JAZZ’s TA Score: 4 bullish, 5 bearish.
- JBIO’s TA Score: 5 bullish, 5 bearish.
Price Growth
JAZZ (@Biotechnology) experienced а +6.83% price change this week, while JBIO (@Biotechnology) price change was +12.56% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
JAZZ is expected to report earnings on Mar 02, 2027.
JBIO is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
JAZZ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with ZYME. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then ZYME could also see price increases.
| Ticker / NAME | Correlation To JAZZ | 1D Price Change % | ||
|---|---|---|---|---|
| JAZZ | 100% | +0.77% | ||
| ZYME - JAZZ | 52% Loosely correlated | +2.11% | ||
| AMLX - JAZZ | 43% Loosely correlated | +2.32% | ||
| DYN - JAZZ | 43% Loosely correlated | -3.76% | ||
| CLDX - JAZZ | 42% Loosely correlated | -1.89% | ||
| JBIO - JAZZ | 41% Loosely correlated | +5.13% | ||
More | ||||
JBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, JBIO has been loosely correlated with IMNM. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if JBIO jumps, then IMNM could also see price increases.
| Ticker / NAME | Correlation To JBIO | 1D Price Change % | ||
|---|---|---|---|---|
| JBIO | 100% | +5.13% | ||
| IMNM - JBIO | 43% Loosely correlated | -3.67% | ||
| ARVN - JBIO | 42% Loosely correlated | +2.37% | ||
| SYRE - JBIO | 42% Loosely correlated | -4.15% | ||
| IMVT - JBIO | 42% Loosely correlated | +1.59% | ||
| ORKA - JBIO | 41% Loosely correlated | +4.72% | ||
More | ||||